CorrellCU.Antipsychotic medications. In: DulcanMK, ed. Dulcan’s Textbook of Child and Adolescent Psychiatry. 2nd ed.Arlington, VA: American Psychiatric Association Publishing; 2016:795-846.
2.
SohnMMogaDCBlumenscheinKTalbertJ.National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. Medicine (Baltimore). 2016;95:e3784.
3.
LoyJHMerrySNHetrickSEStasiakK.Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev. 2017;(8):CD008559.
4.
RettewDCGreenblattJKamonJ, et al. Antipsychotic medication prescribing in children enrolled in Medicaid. Pediatrics. 2015;135:658-665.
5.
CartonLCottencinOLapeyre-MestreM, et al. Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends. Curr Pharm Des. 2015;21:3280-3297.
6.
CrystalSMackieTFentonMC, et al. Rapid growth of antipsychotic prescriptions for children who are publicly insured has ceased, but concerns remain. Health Aff (Millwood). 2016;35:974-982.
7.
VanderwerkerLAkincigilAOlfsonMGerhardTNeese-ToddSCrystalS.Foster care, externalizing disorders, and antipsychotic use among Medicaid-enrolled youths. Psychiatr Serv. 2014;65:1281-1284.
8.
GlesenerDAndersonGLiX, et al. Psychotropic medication patterns for American Indian children in foster care. J Child Adolesc Psychopharmacol. 2018;28:225-231.
9.
BurcuMZitoJMIbeASaferDJ.Atypical antipsychotic use among Medicaid-insured children and adolescents: duration, safety, and monitoring implications. J Child Adolesc Psychopharmacol. 2014;24:112-119.
10.
Leckman-WestinEFinnertyMScholleSH, et al. Differences in Medicaid antipsychotic medication measures among children with SSI, foster care, and income-based aid. J Manag Care Spec Pharm. 2018;24:238-246.
11.
ZitoJMBurcuMIbeASaferDJMagderLS.Antipsychotic use by Medicaid-insured youths: impact of eligibility and psychiatric diagnosis across a decade. Psychiatr Serv. 2013;64:223-229.
12.
BrophySKennedyJFernandez-GutierrezF, et al. Characteristics of children prescribed antipsychotics: analysis of routinely collected data. J Child Adolesc Psychopharmacol. 2018;28:180-191.
13.
ThackerayJCraneDFontanellaCSorterMBaumRApplegateM.A Medicaid quality improvement collaborative on psychotropic medication prescribing for children. Psychiatr Serv. 2018;69:501-504.
14.
De HertMDetrauxJvan WinkelRYuWCorrellCU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8:114-126.
15.
GallingBRoldánANielsenRE, et al. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry. 2016;73:247-259.
16.
EllulPDelormeRCorteseS.Metformin for weight gain associated with second-generation antipsychotics in children and adolescents: a systematic review and meta-analysis. CNS Drugs. 2018;32:1103-1112.
17.
MontejoALArangoCBernardoM, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol. 2017;45:25-34.
18.
CarbonMKaneJMLeuchtSCorrellCU.Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17:330-340.
19.
RayWASteinCMMurrayKT, et al. Association of antipsychotic treatment with risk of unexpected death among children and youths. JAMA Psychiatry. 2019;76:162-171.
20.
American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65:267-272.
21.
WakefieldSAligetiMRachamalluV, et al. Metabolic monitoring of child and adolescent patients on atypical antipsychotics by psychiatrists and primary care providers. Am J Ther. doi:10.1097/MJT.0000000000000853
22.
CeroveckiAMusilRKlimkeA, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs. 2013;27:545-572.
